Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOZANTINIB S-MALATE Cause Oedema? 141 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 141 reports of Oedema have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 0.4% of all adverse event reports for CABOZANTINIB S-MALATE.

141
Reports of Oedema with CABOZANTINIB S-MALATE
0.4%
of all CABOZANTINIB S-MALATE reports
14
Deaths
33
Hospitalizations

How Dangerous Is Oedema From CABOZANTINIB S-MALATE?

Of the 141 reports, 14 (9.9%) resulted in death, 33 (23.4%) required hospitalization, and 2 (1.4%) were considered life-threatening.

Is Oedema Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABOZANTINIB S-MALATE. However, 141 reports have been filed with the FAERS database.

What Other Side Effects Does CABOZANTINIB S-MALATE Cause?

Diarrhoea (8,282) Fatigue (6,819) Off label use (5,245) Nausea (4,341) Decreased appetite (4,076) Blood pressure increased (2,939) Malignant neoplasm progression (2,718) Palmar-plantar erythrodysaesthesia syndrome (2,706) Weight decreased (2,657) Stomatitis (2,560)

What Other Drugs Cause Oedema?

RITUXIMAB (2,791) PREDNISONE (2,721) AMBRISENTAN (2,651) METHOTREXATE (2,244) ADALIMUMAB (2,141) TOCILIZUMAB (1,836) FOLIC ACID (1,781) ABATACEPT (1,754) TREPROSTINIL (1,705) DICLOFENAC (1,691)

Which CABOZANTINIB S-MALATE Alternatives Have Lower Oedema Risk?

CABOZANTINIB S-MALATE vs CAFFEINE CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL CABOZANTINIB S-MALATE vs CALCIFEDIOL CABOZANTINIB S-MALATE vs CALCIPOTRIENE

Related Pages

CABOZANTINIB S-MALATE Full Profile All Oedema Reports All Drugs Causing Oedema CABOZANTINIB S-MALATE Demographics